Pharma Capital
EPIC: SBTX
Market: AIM
52-week High/Low: 17.75p / 8.49p
Sector: Pharma & Biotech
Market Cap: 10.67M

SkinBioTherapeutics plc is developing innovative treatments for human skin using a technology, ‘SkinBiotixTM’ which is derived from the human microbiome. SkinBiotixTM is a scientific platform developed at the University of Manchester which enhances the barrier of skin and protects skin from infection by the common skin pathogen, Staphylococcus aureus (prevalent in MRSA). The company is developing SkinbiotixTM to address a number of markets including a cosmetic product, to enhance the look and feel of ‘sensitive’ skin, an anti-infective product for the healthcare sector and a therapy for Eczema.

SkinBioTherapeutics PLC

www.skinbiotherapeutics.com

Interactive graph

col 3
col 4
col 5
col 6

SkinBioTherapeutics PLC Snapshot

TECHNOLOGY

SkinBioTherapeutics

The Microbiome

The microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa and viruses - that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and it is a fundamental component of human physiology. Changes in the microbiome can trigger changes in human cellular activities, resulting in disease or contribute to its progression.

The Human Microbiome

  • The human body has around 10X more bacteria within it, and on it than human cells
  • The collective name for all the genes in all the bacteria is 'the microbiome'
  • The microbiome consists of around 1000,000 genes – humans have around 23,000
  • The microbiome has huge potential to change how the body functions

Skinbiotix

SkinBioTherapeutics uses lysates (extracts) of probiotic bacteria that have been shown to:

  • Increase the skins barrier integrity by enhancing the formation of multi-protein complexes called ‘tight junctions’. Tight junctions seal the space between adjacent gut cells to prevent the passage of toxins, molecules and ions through these spaces
  • Protect the Skin from infection by outcompeting harmful pathogens
  • Increase the rate of Skin healing in response to injury

 

APPLICATIONS

SkinBioTherapeutics is:

  • Targeting multi billion dollar market opportunities markets
  • Exploiting a critical and gap in the market for microbiome-based applications

 

Martin Hunt
Non-Executive Chairman

Martin has over 30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Martin is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.

 

Dr Cath O'Neill
Chief Executive Officer

Cath is an accomplished biologist and a leader in human-bacterial interactions. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester.

 

Doug Quinn
Chief Financial Officer

Doug has spent the last 15 years involved in start-up and early stage businesses helping to manage them through subsequent levels of growth and secure the requisite funding. Doug has operational experience both within finance and across other business functions as well as considerable corporate finance experience, including in public markets. He was previously CFO at AIM listed Arthro Kinetics Plc and is currently CFO with regenerative medicine company Videregen and prior to joining Skin Biotherapeutics was CFO with University of Manchester spinout Gelexir Healthcare.

 

Stephen O'Hara
Non-Executive Director

Stephen O'Hara spent 20 years working for the National Health Service (NHS) where he was responsible for delivering microbiology services to a large university teaching hospital. Stephen left the NHS in 2000 to set up an internet auction house, Acolyte Biomedica Limited (Acolyte), which developed rapid diagnostics for healthcare acquired infections such as MRSA. Acolyte was sold to 3M in 2007 where Stephen became Director of Microbiology. Stephen left 3M in 2009 to become a Director at Taunton and Somerset Foundation Trust. In 2011 he founded Intelligent Biotech Limited as a vehicle to identify technologies and market opportunities in healthcare, which has enabled him to identify the emerging potential of the human microbiome and set up OptiBiotix. During over 30 years in microbiology and healthcare, Stephen has authored over 40 articles, including chapters in several books, and is the inventor on a number of patents. He has at various times been editorial referee for the Journal of Medical Pathology and Journal of Clinical Microbiology.

 

Dr Cathy Prescott
Non-Executive Director

Cathy has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., non-executive Director Videregen Ltd., chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member Babraham Institute and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme 'Cellular Therapies from bench to market' and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).

Significant Shareholders

As at 5th April 2017, significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc, and shareholdings of any other directors are detailed below:

  Number Ordinary Shares %
OptiBiotix Health Plc 49,794,190 41.9%
Seneca Partners Limited 17,388,889 14.6%
The University of Manchester 8,511,438 7.2%
Dr. Catherine O'Neill 5,256,989 4.4%
Professor Andrew McBain 5,201,434 4.4%

Director Shareholders

  Number Ordinary Shares %
Dr Catherine O’Neill 5,256,989 4.4%
Martin Hunt 444,444 0.4%
Douglas Quinn 444,444 0.4%

 

SkinBioTherapeutics PLC
15 Silk House
Park Green
Macclesfield
Cheshire
SK11 7QJ

Registered Office

SkinBioTherapeutics plc
15 Silk House
Park Green
Macclesfield
SK11 7QJ
United Kingdom
+44 (0)161 4682 760

Nominated Adviser

Cairn Financial Advisers LLP
Cheyne House, Crown Court
62-63 Cheapside
London
EC2V 6AX
United Kingdom
+44 (0)20 7213 0880

Broker

Turner Pope Investments (TPI) Limited
6th Floor, Beckett House
36 Old Jewry
London
EC2R 8DD
United Kingdom
+44 (0)20 3621 4120

Financial PR

Instinctif Partners
65 Gresham Street
London
EC2V 7NQ
United Kingdom
+44 (0)20 7457 2020

Registrar

Share Registrars Limited
The Courtyard
17 West Street
Farnham
GU9 7DR
United Kingdom
+44 (0)1252 821 390

Accountants and Auditors

Jeffreys Henry LLP
Finsgate
5-7 Cranwood Street
London
EC1V 9EE
United Kingdom
+44 (0)20 7309 2222

Solicitors to the Company as to English law

Turner Parkinson LLP
Hollins Chambers
64a Bridge Street
Manchester
M3 3BA

SkinBioTherapeutics PLC Timeline

View All

Market Reports Including SBTX

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.